Literature DB >> 36137679

POTS May Be Underestimated in Post-COVID Assessments.

Mitchell G Miglis, Lauren E Stiles, Satish R Raj.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 36137679      PMCID: PMC9484477          DOI: 10.1016/j.jacc.2022.04.068

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   27.203


× No keyword cloud information.
We thank Jamal et al for describing their prospective evaluation of autonomic disorders in individuals with postacute sequela of COVID-19 (PASC). The authors reported that a minority of individuals with PASC met criteria for postural orthostatic tachycardia syndrome (POTS), while a majority demonstrated provoked orthostatic intolerance (POI) in response to a prolonged head-up tilt table (HUTT) and nitroglycerin. The authors’ protocol might underestimate the prevalence of POTS in PASC for 2 reasons. First, beta-blockers were not discontinued before the HUTT. Although no patients diagnosed with POTS were on beta-blockers, some individuals not meeting the POTS heart rate criterion were on beta-blockers during HUTT. , It is possible that some of those individuals might have had excessive orthostatic tachycardia if beta-blockers were held for HUTT. Second, whereas the diagnosis of POTS requires both the excessive orthostatic tachycardia and orthostatic intolerance symptoms, the published criteria do not require these symptoms to be present during the HUTT itself. , The assessment of POI in this study is novel and interesting. Although nitroglycerin provocation is a standard part of the Italian HUTT protocol for assessing vasovagal syncope, symptoms are not usually reported in the absence of a vasovagal reaction. Nitroglycerin likely increases the sensitivity for orthostatic intolerance symptoms (and perhaps hypotension) but may lower the specificity for the reproduction of clinical symptoms. To interpret these findings, data are needed on the provocation of POI in healthy control subjects. In addition, lack of continuous beat-to-beat blood pressure and heart rate monitoring might have reduced the sensitivity for diagnosing orthostatic disorders on HUTT. Finally, it is not clear how PASC patients were recruited for HUTT. If only patients with orthostatic intolerance were referred, it is difficult to assess the true prevalence of orthostatic intolerance in PASC. We ultimately thank the authors for their contribution and look forward to more research on autonomic complications of PASC.
  3 in total

1.  2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.

Authors:  Robert S Sheldon; Blair P Grubb; Brian Olshansky; Win-Kuang Shen; Hugh Calkins; Michele Brignole; Satish R Raj; Andrew D Krahn; Carlos A Morillo; Julian M Stewart; Richard Sutton; Paola Sandroni; Karen J Friday; Denise Tessariol Hachul; Mitchell I Cohen; Dennis H Lau; Kenneth A Mayuga; Jeffrey P Moak; Roopinder K Sandhu; Khalil Kanjwal
Journal:  Heart Rhythm       Date:  2015-05-14       Impact factor: 6.343

2.  Prospective Evaluation of Autonomic Dysfunction in Post-Acute Sequela of COVID-19.

Authors:  Sameer M Jamal; David B Landers; Steven M Hollenberg; Zoltan G Turi; Taya V Glotzer; Jana Tancredi; Joseph E Parrillo
Journal:  J Am Coll Cardiol       Date:  2022-04-02       Impact factor: 27.203

3.  Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1.

Authors:  Steven Vernino; Kate M Bourne; Lauren E Stiles; Blair P Grubb; Artur Fedorowski; Julian M Stewart; Amy C Arnold; Laura A Pace; Jonas Axelsson; Jeffrey R Boris; Jeffrey P Moak; Brent P Goodman; Kamal R Chémali; Tae H Chung; David S Goldstein; Andre Diedrich; Mitchell G Miglis; Melissa M Cortez; Amanda J Miller; Roy Freeman; Italo Biaggioni; Peter C Rowe; Robert S Sheldon; Cyndya A Shibao; David M Systrom; Glen A Cook; Taylor A Doherty; Hasan I Abdallah; Anil Darbari; Satish R Raj
Journal:  Auton Neurosci       Date:  2021-06-05       Impact factor: 2.355

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.